| P50 | author | George Perry | Q5543353 |
| | Daniela Galimberti | Q32425219 |
| | Justin J. Greenlee | Q56979084 |
| | 'alim J Beveridge | Q57425409 |
| | Barbara Borroni | Q59662127 |
| | Xiongwei Zhu | Q66905953 |
| P2093 | author name string | Ajay Singh | |
| | Chinmay K Mukhopadhyay | |
| | Neena Singh | |
| | Joseph Wong | |
| | Janis Blevins | |
| | Christine Schmotzer | |
| | Swati Haldar | |
| P2860 | cites work | Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples | Q24289511 |
| | Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease | Q24298553 |
| | A systems approach to prion disease | Q24656032 |
| | Two-sided confidence intervals for the single proportion: comparison of seven methods | Q28271313 |
| | Ultra-efficient PrP(Sc) amplification highlights potentialities and pitfalls of PMCA technology | Q28478072 |
| | Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles | Q28589989 |
| | Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach | Q29614698 |
| | The expanding universe of prion diseases | Q33239695 |
| | Abnormal brain iron homeostasis in human and animal prion disorders | Q33417668 |
| | Prion protein (PrP) knock-out mice show altered iron metabolism: a functional role for PrP in iron uptake and transport | Q33476856 |
| | Alpha-synuclein is a cellular ferrireductase | Q33798034 |
| | Redox control of prion and disease pathogenesis | Q33830151 |
| | Decreased CSF transferrin in sCJD: a potential pre-mortem diagnostic test for prion disorders | Q33847248 |
| | Rapidly progressive diffuse Lewy body disease | Q33870090 |
| | A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease | Q33903249 |
| | Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease | Q33933305 |
| | Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study | Q34059789 |
| | Intracellular iron transport and storage: from molecular mechanisms to health implications | Q34100135 |
| | Evidence that a panel of neurodegeneration biomarkers predicts vasospasm, infarction, and outcome in aneurysmal subarachnoid hemorrhage | Q34103510 |
| | Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. | Q34161515 |
| | Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. | Q34181256 |
| | Altered Prion protein expression pattern in CSF as a biomarker for Creutzfeldt-Jakob disease | Q34257239 |
| | Iron and neurodegenerative disorders | Q34317918 |
| | Iron and Parkinson's disease | Q34529356 |
| | Role of metal dyshomeostasis in Alzheimer's disease | Q35051952 |
| | Iron and neurodegeneration in multiple sclerosis | Q35379973 |
| | Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease | Q35462665 |
| | CSF biomarkers for Alzheimer's disease: current utility and potential future use. | Q35600993 |
| | The metabolism of neuronal iron and its pathogenic role in neurological disease: review | Q35754462 |
| | Change in the characteristics of ferritin induces iron imbalance in prion disease affected brains | Q35777814 |
| | Clinico-pathological correlations of the most common neurodegenerative dementias. | Q35923461 |
| | Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment | Q36041047 |
| | Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology. | Q36475223 |
| | Clinical overlap between Jakob-Creutzfeldt disease and Lewy body disease | Q36662448 |
| | Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics | Q36755348 |
| | Rapidly progressive dementia | Q36894419 |
| | Iron trafficking inside the brain | Q36978252 |
| | Prion protein modulates cellular iron uptake: a novel function with implications for prion disease pathogenesis | Q37087487 |
| | Human variant Creutzfeldt-Jakob disease and sheep scrapie PrP(res) detection using seeded conversion of recombinant prion protein | Q37285506 |
| | Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases | Q37376532 |
| | Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease | Q37381059 |
| | Prion protein and metal interaction: physiological and pathological implications | Q37600574 |
| | Brain iron metabolism and its perturbation in neurological diseases. | Q37784423 |
| | The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review | Q37790529 |
| | Rapidly progressive Alzheimer disease | Q37930831 |
| | Sporadic human prion diseases: molecular insights and diagnosis | Q38019773 |
| | Prion propagation, toxicity and degradation | Q38021894 |
| | Rapidly progressive dementia | Q42034203 |
| | Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease | Q42472074 |
| | Thorough work-up and new diagnostic criteria needed for CJD. | Q42792777 |
| | Reaction mechanisms of the multicopper oxidase CueO from Escherichia coli support its functional role as a cuprous oxidase. | Q43188797 |
| | Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system | Q44438522 |
| | Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease | Q44480549 |
| | Modeling the kinetics of Fe(II) oxidation in the presence of citrate and salicylate in aqueous solutions at pH 6.0-8.0 and 25 degrees C. | Q44775852 |
| | Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. | Q45288825 |
| | CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. | Q45923691 |
| | Copper proteins and ferroxidases in human plasma and that of wild-type and ceruloplasmin knockout mice | Q46085215 |
| | Ferritin subunits in CSF are decreased in restless legs syndrome | Q46928654 |
| | HO-1/BVR-a system analysis in plasma from probable Alzheimer's disease and mild cognitive impairment subjects: a potential biochemical marker for the prediction of the disease | Q47403734 |
| | Likelihood ratios with confidence: sample size estimation for diagnostic test studies | Q47435977 |
| | The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt-Jakob disease | Q47839278 |
| | Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance | Q48181910 |
| | Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease | Q48398841 |
| | Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders | Q48560437 |
| | Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. | Q53290882 |
| | Rapidly progressive Alzheimer's disease and elevated 14-3-3 proteins in cerebrospinal fluid. | Q53294163 |
| | Dementia with Lewy bodies in a neuropathologic series of suspected Creutzfeldt-Jakob disease | Q62381837 |
| | The Contribution of Citrate to the Ferroxidase Activity of Serum | Q72404641 |
| | Human transmissible spongiform encephalopathies | Q77652092 |
| | The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element | Q79838827 |
| | EEG findings in dementia with Lewy bodies causing diagnostic confusion with sporadic Creutzfeldt-Jakob disease | Q81311711 |
| | Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients | Q81854484 |
| | Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention | Q82968961 |
| P433 | issue | 14 | |
| P921 | main subject | diagnosis | Q16644043 |
| | biomarker | Q864574 |
| P304 | page(s) | 1662-1675 | |
| P577 | publication date | 2013-04-16 | |
| P1433 | published in | Antioxidants & Redox Signaling | Q4775078 |
| P1476 | title | A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD. | |
| P478 | volume | 19 | |